首页> 外文期刊>Journal of Drug Delivery and Therapeutics >Development of Extended Release Formulations of Ilaprazole Tablets
【24h】

Development of Extended Release Formulations of Ilaprazole Tablets

机译:依帕拉唑片缓释制剂的研制

获取原文
           

摘要

Extended release products are designed to release their medication in a controlled manner at a predetermined rate, duration, and location to achieve and maintain optimum therapeutic blood levels of a drug. The objective of the study is to formulate and evaluate Ilaprazole Controlled release tablets comparable to the innovator product. F1-F9 formulations were prepared using varying concentrations of super disintegrates like Crospovidone, Croscarmellose sodium and Sodium starch glycolate in different concentrations. Based on the hardness, friability, weight variation, drug content, F6 formulation was found to be optimised. The selected F6 formulation was sub coated with HPMC P 50 and followed by enteric coating with Acryl-EZE-80 (Eudragit L100-55). 3 formulations (F10-F12) were prepared by using coating. Among the three formulations, F11 formulation was found to be best. FTIR studies were carried out to find out drug and excipient compatibility studies, the studies revealed that there were no interactions. DSC studies also carried out to demonstrate any changes in physical forms of the drug molecule.
机译:延长释放产品被设计为以预定的速率,持续时间和位置以受控方式释放其药物,以实现并维持药物的最佳治疗性血液水平。研究的目的是配制和评估与创新产品相当的依拉唑控释片剂。 F1-F9制剂使用不同浓度的不同浓度的超级崩解剂(如Crospovidone,Croscarmellose钠和淀粉羟乙酸钠)制备。根据硬度,脆性,重量变化,药物含量,发现F6配方最优化。所选的F6制剂用HPMC P 50进行亚包衣,然后用Acryl-EZE-80(Eudragit L100-55)进行肠溶衣。使用涂料制备了3种配方(F10-F12)。在这三种配方中,发现F11配方是最好的。进行了FTIR研究以发现药物和赋形剂的相容性研究,该研究表明没有相互作用。还进行了DSC研究以证明药物分子物理形式的任何变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号